Therefore, we hypothesized that TSPAN7 may affect the binding of PDL1 to PD1 in tumor cells by changing the morphology of tumor cells, and then affect the efficacy of anti-PDL1 immunotherapy. Here, PDCD1 is linked to neoplasm.